Breaking Finance News

RBC Capital announced Zimmer Biomet (NYSE:ZBH), bumping up its stock price target to $140.00 today

In a report released on Wednesday June 21, 2017 RBC Capital increased the stock price target of Zimmer Biomet (NYSE:ZBH) from $133.00 to $140.00 reporting a possible upside of 0.10%.

Previously on 6/12/2017, Citigroup released a statement about Zimmer Biomet (NYSE:ZBH) increased the target price from $108.00 to $130.00. At the time, this indicated a possible upside of 0.04%.

Just yesterday Zimmer Biomet (NYSE:ZBH) traded -0.45% lower at $127.22. Zimmer Biomet’s 50-day moving average is $114.88 and its 200-day moving average is $120.74. The last stock price is up -4.37% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 1,626,722 shares of ZBH traded hands, up from an average trading volume of 1,440,590

Recent Performance Chart

Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet has 52 week low of $95.63 and a 52 week high of $133.49 with a PE ratio of 32.89 and has a market capitalization of $0.

In addition to RBC Capital reporting its stock price target, a total of 23 brokerages have issued a research note on the company. The average stock price target is $127.52 with 9 brokerages rating the stock a strong buy, 10 brokerages rating the stock a buy, 9 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 1 brokerage rating the stock a sell.

Brief Synopsis On Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.